gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Vasoactive intestinal peptide receptor 1

VPAC1, HVR1, vasoactive intestinal peptide receptor
This gene encodes a receptor for vasoactive intestinal peptide, a small neuropeptide. Vasoactive intestinal peptide is involved in smooth muscle relaxation, exocrine and endocrine secretion, and water and ion flux in lung and intestinal epithelia. Its actions are effected through integral membrane receptors associated with a guanine nucleotide binding protein which activates adenylate cyclase. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011] (from NCBI)
Top mentioned proteins: Vasoactive Intestinal Peptide, VPAC2, PACAP, ACID, HAD
Papers on VPAC1
Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.
Jensen et al., Bethesda, United States. In Curr Opin Endocrinol Diabetes Obes, Feb 2016
PURPOSE OF REVIEW: To summarize the roles of vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase activating polypeptide (PACAP) and their receptors (VPAC1, VPAC2, PAC1) in human tumors as well as their role in potential novel treatments.
Antibody response to the hypervariable region-1 interferes with broadly neutralizing antibodies to hepatitis C virus.
Foung et al., Paris, France. In J Virol, Feb 2016
UNASSIGNED: The hypervariable region-1 (HVR1) (amino acids (aa) 384-410) on the E2 glycoprotein of hepatitis C virus contributes to persistent infection by evolving escape mutations that attenuate binding of inhibitory antibodies and by blocking access of broadly neutralizing antibodies to their epitopes.
Network analysis of the chronic Hepatitis C virome defines HVR1 evolutionary phenotypes in the context of humoral immune responses.
Fanning et al., Cork, Ireland. In J Virol, Jan 2016
UNASSIGNED: The hypervariable region 1 (HVR1) of Hepatitis C virus (HCV) comprises the first 27 N-terminal amino acid residues of E2.
Multiregion Deep Sequencing of Hepatitis C Virus: An improved Approach for Genetic Relatedness Studies.
Rahal et al., Ribeirão Preto, Brazil. In Infect Genet Evol, Jan 2016
Genetic relatedness studies primarily rely on information obtained from the rapidly evolving HCV hypervariable region 1 (HVR1).
Genetic blockade of the dopamine D3 receptor enhances hippocampal expression of PACAP and receptors and alters their cortical distribution.
Castorina et al., Catania, Italy. In Neuroscience, Jan 2016
Consistently, PAC1, VPAC1 and VPAC2 IRs were variably redistributed in CX, with a general upregulation in cortical layers II-IV in knockout animals.
VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model.
Ramhorst et al., Buenos Aires, Argentina. In Sci Rep, Dec 2015
Pregnancy induced the expression of VIP, VPAC1 and VPAC2 in the uterus from CBA/J × DBA/2 mating females on day 8.5 of gestation compared with non-pregnant mice.
The SNP rs9677 of VPAC1 gene is associated with glycolipid control and heart function in female patients with type 2 diabetes: A follow-up study.
Morano et al., Roma, Italy. In Nutr Metab Cardiovasc Dis, Nov 2015
BACKGROUND AND AIMS: In a previous study, the single-nucleotide polymorphism (SNP) rs9677, mapped in the 3'-UTR of vasoactive intestinal peptide receptor 1 (VPAC1) gene, was found to be associated with type 2 diabetes (T2D) in Caucasian women.
Therapeutic potential of PACAP for neurodegenerative diseases.
Xin et al., In Cell Mol Biol Lett, Jun 2015
PACAP can initiate multiple signaling pathways through binding with three class B G-protein coupled receptors, PAC1, VPAC1 and VPAC2.
New approaches in the treatment of hypertension.
Schmieder et al., Jishou, China. In Circ Res, Apr 2015
New drug classes, eg, inhibitors of vasopeptidases, aldosterone synthase and soluble epoxide hydrolase, agonists of natriuretic peptide A and vasoactive intestinal peptide receptor 2, and a novel mineralocorticoid receptor antagonist are in phase II/III of development, while inhibitors of aminopeptidase A, dopamine β-hydroxylase, and the intestinal Na(+)/H(+) exchanger 3, agonists of components of the angiotensin-converting enzyme 2/angiotensin(1-7)/Mas receptor axis and vaccines directed toward angiotensin II and its type 1 receptor are in phase I or preclinical development.
Sleep and circadian rhythm disruption and recognition memory in schizophrenia.
Peirson et al., Oxford, United Kingdom. In Methods Enzymol, 2014
Similar phenotypes are seen in schizophrenia-relevant genetic mouse models, such as synaptosomal associated protein of 25 kDa (Snap-25) point mutant mice, vasoactive intestinal peptide receptor 2 (Vipr2) knockout mice, and neuregulin 1 (Nrg1)-deficient mice.
Advent and recent advances in research on the role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the regulation of gonadotropic hormone secretion of female rats.
Szabó et al., Budapest, Hungary. In J Mol Neurosci, 2014
PACAP activates three distinct receptor types: G-protein coupled PAC1, VPAC1, and VPAC2 with seven transmembrane domains.
Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases.
Seo et al., Ch'unch'ŏn, South Korea. In Bmb Rep, 2014
PACAP is widely distributed in the central and peripheral nervous systems and acts as a neurotransmitter, neuromodulator, and neurotrophic factor via three major receptors (PAC1, VPAC1, and VPAC2).
Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.
Sánchez-Chapado et al., Alcalá de Henares, Spain. In Histol Histopathol, 2012
The overexpression of VPAC1 and VPAC2 receptors and COX-2 in cancer tissue gives them a potential role as targets for diagnosis of prostate cancer.
Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction.
Couvineau et al., Paris, France. In Faseb J, 2012
hree residues play an important role in VPAC1 interaction with the first histidine residue of VIP. These data demonstrate that VIP and PG97-269 bind to distinct domains of VPAC1
Gender-dependent association of type 2 diabetes with the vasoactive intestinal peptide receptor 1.
Sorrentino et al., Roma, Italy. In Gene, 2012
The genetic association reported here indicates that VIP/VPAC1 signaling can be a relevant pathway in the pathogenesis of type 2 diabetes in females
RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.
Prieto et al., Alcalá de Henares, Spain. In Mol Cell Endocrinol, 2012
silencing of VPAC1 receptor inhibits vasoactive intestinal peptide effects on both EGF receptor and HER2 transactivation and vascular endothelial growth factor secretion in human breast cancer cells
Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjögren's syndrome.
Leirós et al., Buenos Aires, Argentina. In Clin Exp Immunol, 2011
results support that decline in VIP/VPAC local levels may influence survival/apoptosis intracellular set point in NOD acinar cells and their clearance, contributing to gland homeostasis loss in a model of Sjogren's syndrome
Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia.
Sebat et al., New York City, United States. In Nature, 2011
All duplications overlapped or were located within 89 kilobases upstream of the vasoactive intestinal peptide receptor gene VIPR2.
Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery.
Vaudry et al., Mont-Saint-Aignan, France. In Pharmacol Rev, 2009
Two types of PACAP binding sites have been characterized: type I binding sites exhibit a high affinity for PACAP and a much lower affinity for VIP, whereas type II binding sites have similar affinity for PACAP and VIP.
Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.
Vaudry et al., Mont-Saint-Aignan, France. In Pharmacol Rev, 2000
Type I binding sites exhibit a high affinity for PACAP and a much lower affinity for VIP whereas type II binding sites have similar affinity for PACAP and VIP.
share on facebooktweetadd +1mail to friends